CXCR4 and neoplasm: If such a tumor sink effect also occurs in patients injected with [68Ga]PentixaFor, this may have a relevant impact on “hot” and “cold” therapies targeting CXCR4, e.g., by safely increasing the amount of therapeutic activity but reducing side effects in organs with normal biodistribution [33].